Trans-capsular administration of high specificity cytokine...

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 31/436 (2006.01) A61K 31/198 (2006.01) A61K 38/30 (2006.01) A61K 39/395 (2006.01) A61P 19/02 (2006.01)

Patent

CA 2534327

The present invention relates to trans-capsularly administering into a diseased joint a high specificity antagonist selected from the group consisting of: i) an inhibitor of a pro-inflammatory interleukin; ii) an inhibitor of TNF-alpha synthesis; iii) an inhibitor of membrane-bound TNF- alpha; iv) an inhibitor of a natural receptor of TNF-alpha; v) an inhibitor of NO synthase, vi) an inhibitor of PLA2 enzyme; vii) an anti-proliferative agent; viii) an anti-oxidant; ix) an apoptosis inhibitor selected from the group consisting of EPO mimetic peptides, EPO mimetibodies, IGF-1, IFG-II, and caspase inhibitors, and x) an inhibitor of MMPs; and xi) an inhibitor of p38 kinase. Conpounds include Rapamycin, NG-Monomethyl-L-Arginine, Infliximab, L- NIL, IGF-1, IGF-2.

La présente invention concerne l'administration transcapsulaire, dans une articulation malade, d'antagonistes à activité spécifique élevée sélectionnés dans le groupe constitué par i) un inhibiteur d'une interleukine pro-inflammatoire; ii) un inhibiteur de synthèse du TNF-a; iii) un inhibiteur du TNF-a membranaire; iv) un inhibiteur du récepteur naturel du TNF-a; v) un inhibiteur de la NO synthase; vi) un inhibiteur de l'enzyme PLA¿2?; vii) un agent antiprolifératif; viii) un anti-oxydant; ix) un inhibiteur d'apoptose sélectionné dans le groupe constitué par des peptides mimétiques d'EPO, des corps mimétiques d'EPO, et des inhibiteurs d'IGF-1, d'IFG-II et de la caspase; x) un inhibiteur de MMP; et xi) un inhibiteur de la p38 kinase.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Trans-capsular administration of high specificity cytokine... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Trans-capsular administration of high specificity cytokine..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Trans-capsular administration of high specificity cytokine... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1759582

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.